The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
about
Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infectionPathogenesis of human immunodeficiency virus infectionT helper cell activation and human retroviral pathogenesisLaboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosisRecombinant gp120 induces IL-10 in resting peripheral blood mononuclear cells; correlation with the induction of other cytokinesLong-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infectionUnderstanding frailty, aging, and inflammation in HIV infectionSoluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010Distribution of lymphocyte subsets in healthy human immunodeficiency virus-negative adult Ethiopians from two geographic localesDecreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional studyCD4 immunophenotyping in HIV infection.Plasma proteome analysis in HTLV-1-associated myelopathy/tropical spastic paraparesis.Soluble IL-2 receptor and tumour necrosis factor-alpha in plasma of haemophilia patients infected with HIV.Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control.Neuropsychological abnormalities in AIDS and asymptomatic HIV seropositive patients.Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients.Immunohematological reference ranges for adult Ethiopians.Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies.Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatientsSerial MRI of the brain in asymptomatic patients infected with HIV: results from the UCMSM/Medical Research Council neurology cohort.Soluble IL-2 receptor and beta-2 microglobulin as possible serologic markers of neurologic disease in HTLV-1 infection.Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.Immune Activation: Contribution to AIDS-Associated Non-Hodgkin LymphomaMemories of John Fahey and His Contributions to the Multicenter AIDS Cohort Study (MACS).Adoption of single-platform technologies for enumeration of absolute T-lymphocyte subsets in peripheral bloodMonitoring patients with HIV diseaseMonitoring of lymphocyte subpopulation changes in the assessment of HIV infection.Defective IgG2 response to Pneumovax in HIV seropositive patients.Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men.Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infectionVariables that affect assays for plasma cytokines and soluble activation markers.Evaluation of TruCount absolute-count tubes for determining CD4 and CD8 cell numbers in human immunodeficiency virus-positive adults. Site Investigators and The NIAID DAIDS New Technologies Evaluation GroupLevels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures.Mode of delivery and postpartum HIV-1 disease progression and mortality in a Kenyan cohort.Can early therapy reduce inflammation?Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissueInnate immunity against HIV: a priority target for HIV prevention researchSoluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
P2860
Q24550678-1CCB50B2-BE46-4A33-9AC8-8F6B5ADFE829Q24634681-D7A3E28F-7393-4BCC-B661-857F224F274DQ24650854-DD6EBC80-A18F-4B9A-8CB5-B3C6079E47F5Q24672191-2DB9D352-55E3-489C-BE27-2869B666E96AQ24681688-E270004A-815F-45DA-80ED-EF98653D6298Q24799835-069119D3-9A9C-420C-B9B6-7E77F9FF56FDQ27021143-B71BD6CB-0060-4F98-ABDC-8B3AF4704F29Q27690715-9CEAB7C4-6CE8-40CB-B0DF-E68C0EE15D0DQ28362961-4FA962DB-8879-4C55-8895-191AFCDAD80DQ28473151-7977A043-162C-4308-B00E-F5F998DD7652Q30372724-EA2C8963-6572-4359-B52F-E2F83B422336Q31033564-9BC593F0-BC44-4756-AE2A-B8E9EDAE9FF7Q33277868-1984BCCA-7889-4E90-8E9F-61180311F96FQ33533743-1125CD88-A3E4-461D-8D71-D16CC4DBA7A4Q33571769-8764A61B-173C-4D60-A573-34697EEEFD5FQ33591573-DBE001D7-08F6-4E38-981F-F84ED449F651Q33608661-31D3906D-0C0D-4E90-8F50-7F87185A1573Q33637326-A84EEC0F-1E5B-434C-85D9-EFC86FAE138DQ33638209-0CAE1CF8-60EB-414B-8120-14DB38B9F810Q33649753-A3BFC494-4A38-4E38-A921-F0C27E5C63A2Q33692547-523D2648-B47D-42AE-A207-2BE64A931ED6Q33731194-3DF236B5-337D-4D80-81A3-5EBFF52D88A2Q33777159-C1BB575D-64C6-406C-B86C-E7D651D6C000Q33780566-FC18DA8A-5047-4EE5-942C-F1437A46B66DQ33887336-B81C54A3-3ADD-4BC5-8D31-242EE85C5FF2Q33893995-8967F3A0-7E8D-4E20-ACB7-AE14F946A68EQ33911906-A94EF32A-53EE-425A-853A-08C651D74926Q33925492-7F5AF87E-4C12-482A-B241-66AD440E1BBCQ33932583-9621B02F-9879-4012-8BCC-141B41B9C595Q33934549-828A545E-3850-4874-9BF8-6856AE39BB26Q33935910-7395BB97-31AF-4F13-BE56-074AE7BCD747Q33997410-63F0E354-4ACF-4297-A32A-2EE199A750C0Q33997552-9E8C4513-4EAA-4249-BBDA-069541DF9881Q33998300-BD1F2691-23BD-48CB-B22F-6E1DDA37BE00Q33999560-2D2D5A54-3685-4384-902E-21ED5EFB1B59Q34048397-E085099F-A130-402D-83A4-1801B59A4E6FQ34159822-D2D90BB1-DB25-40DC-8DBA-081DF841D16FQ34176667-3216857A-2560-43E8-A554-94C5CB483F12Q34243462-7FC69FB6-58A2-4F90-B79D-0AC712102E8BQ34315579-35B6B3D8-5C55-4C57-9F86-7E9A1A3DA991
P2860
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
The prognostic value of cellul ...... immunodeficiency virus type 1.
@en
The prognostic value of cellul ...... immunodeficiency virus type 1.
@nl
type
label
The prognostic value of cellul ...... immunodeficiency virus type 1.
@en
The prognostic value of cellul ...... immunodeficiency virus type 1.
@nl
prefLabel
The prognostic value of cellul ...... immunodeficiency virus type 1.
@en
The prognostic value of cellul ...... immunodeficiency virus type 1.
@nl
P2093
P1476
The prognostic value of cellul ...... immunodeficiency virus type 1.
@en
P2093
Nishanian P
P304
P356
10.1056/NEJM199001183220305
P407
P577
1990-01-01T00:00:00Z